Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sunil Sharma

Showing results (381-390 of 429) with videos related to

Pageof 43
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 16, 2003
Dose-escalating and pharmacological study of oxaliplatin in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group StudyChris H Takimoto, Scot C Remick, Sunil Sharma, et al.
Journal for Immunotherapy of Cancer|March 18, 2020
A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti-PD-1 antibody, in patients with advanced solid tumorsAung Naing, Justin F Gainor, Hans Gelderblom, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 9, 2016
Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder CancerChristophe Massard, Michael S Gordon, Sunil Sharma, et al.
Nature Communications|May 31, 2022
Long-term hepatitis B virus infection of rhesus macaques requires suppression of host immunitySreya Biswas, Lauren N Rust, Jochen M Wettengel, et al.
The New England Journal of Medicine|June 3, 2026
Targeting of Wnt-β-Catenin Pathway in Recurrent AmeloblastomaSamuel J Klempner, Moh'd Khushman, Kyriakos P Papadopoulos, et al.
Blood Advances|February 5, 2025
Targeting RNA modification and mitochondrial metabolism cross talk in leukemic stem cells with CDK7 inhibitor TGN-1062Hyunjun Kang, Lianjun Zhang, Mohan R Kaadige, et al.
BMC Cancer|September 14, 2017
A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancerKerry Lynn Reynolds, Philippe L Bedard, Se-Hoon Lee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 12, 2013
Clinical Cancer Advances 2013: Annual Report on Progress Against Cancer from the American Society of Clinical OncologyJyoti D Patel, Lada Krilov, Sylvia Adams, et al.
British Journal of Cancer|June 5, 2021
Essential role of the histone lysine demethylase KDM4A in the biology of malignant pleural mesothelioma (MPM)Moshe Lapidot, Abigail E Case, Ellen L Weisberg, et al.
The Lancet. Oncology|March 15, 2016
Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trialDong-Wan Kim, Ranee Mehra, Daniel S W Tan, et al.
Pageof 43

Showing results (381-390 of 429) with videos related to

Sort By:
Pageof 43
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 16, 2003
Dose-escalating and pharmacological study of oxaliplatin in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group StudyChris H Takimoto, Scot C Remick, Sunil Sharma, et al.
Journal for Immunotherapy of Cancer|March 18, 2020
A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti-PD-1 antibody, in patients with advanced solid tumorsAung Naing, Justin F Gainor, Hans Gelderblom, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 9, 2016
Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder CancerChristophe Massard, Michael S Gordon, Sunil Sharma, et al.
Nature Communications|May 31, 2022
Long-term hepatitis B virus infection of rhesus macaques requires suppression of host immunitySreya Biswas, Lauren N Rust, Jochen M Wettengel, et al.
The New England Journal of Medicine|June 3, 2026
Targeting of Wnt-β-Catenin Pathway in Recurrent AmeloblastomaSamuel J Klempner, Moh'd Khushman, Kyriakos P Papadopoulos, et al.
Blood Advances|February 5, 2025
Targeting RNA modification and mitochondrial metabolism cross talk in leukemic stem cells with CDK7 inhibitor TGN-1062Hyunjun Kang, Lianjun Zhang, Mohan R Kaadige, et al.
BMC Cancer|September 14, 2017
A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancerKerry Lynn Reynolds, Philippe L Bedard, Se-Hoon Lee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 12, 2013
Clinical Cancer Advances 2013: Annual Report on Progress Against Cancer from the American Society of Clinical OncologyJyoti D Patel, Lada Krilov, Sylvia Adams, et al.
British Journal of Cancer|June 5, 2021
Essential role of the histone lysine demethylase KDM4A in the biology of malignant pleural mesothelioma (MPM)Moshe Lapidot, Abigail E Case, Ellen L Weisberg, et al.
The Lancet. Oncology|March 15, 2016
Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trialDong-Wan Kim, Ranee Mehra, Daniel S W Tan, et al.
Pageof 43